KIMSHEALTH performs two allogeneic stem cell transplants, one a complex half-match procedure
Allogeneic stem cell transplant involves replacing diseased stem cells in the bone marrow with healthy ones from a donor.
In haploidentical or half-match transplants, the recipient shares only a partial genetic match with the donor, who is usually a family member.
The half-match transplant was performed on a 37-year-old woman diagnosed with acute myeloid leukemia (AML). Although her sister was the donor, their incompatible blood groups made the procedure particularly complex.
To further compound the challenge, the patient was also battling multi-drug resistant bacterial infections and aspergillosis — a fungal infection that typically affects immunocompromised individuals.
After the transplant, she contracted cytomegalovirus (CMV), a viral infection, for which she was treated with antivirals. Despite these life-threatening complications, the patient made a full recovery. A bone marrow assessment conducted 100 days after the transplant confirmed that she was disease-free.
The second successful transplant involved a 63-year-old male patient, also diagnosed with AML, who underwent an allogeneic transplant from a fully matched sibling donor.
Despite the age- related risks and potential complications involved, the patient showed remarkable progress and is in remission as of day 100 post-transplant., the press release said.
'Haploidentical transplants, especially in cases where blood groups are incompatible, demand an advanced skill set and precision,' it said.
The treatment was led by Bijay P Nair, Senior Consultant , Department of Clinical Hematology and Bone Marrow Transplant . The team Included K. S. Lekshmon and Aswin V. Nair, Associate Consultants and Sanooja Pinki, Department of Transfusion Medicine, KIMSHEALTH.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
5 days ago
- Hans India
Deadly blood cancer can now be detected early with blood test: Study
A team of Israeli and American scientists have developed a groundbreaking blood test that may soon revolutionize the early detection of leukaemia and other blood-related disorders. The test, which analyzes a simple blood sample, could eliminate the need for invasive bone marrow biopsies currently used in diagnosis. Published in the prestigious journal Nature Medicine, the study was led by researchers from the Weizmann Institute of Science in Israel. The team focused their work on identifying early indicators of myelodysplastic syndrome (MDS), an age-related condition in which blood-forming stem cells fail to develop correctly. MDS is particularly dangerous as it can lead to severe anaemia and progress into acute myeloid leukaemia (AML), a fast-growing type of blood cancer prevalent among adults. Currently, diagnosing MDS requires a painful and intrusive procedure — bone marrow sampling — which involves drilling into the pelvic bone under local anaesthesia. For many patients, especially older adults, this process is uncomfortable and distressing. The new research offers a promising alternative. The scientists discovered that rare blood-forming stem cells, which occasionally escape from the bone marrow and circulate in the bloodstream, carry crucial genetic clues about the early development of MDS. Using advanced single-cell genetic sequencing techniques, the researchers successfully decoded the information contained within these rare cells — all from a routine blood draw. One of the most remarkable findings was that these circulating stem cells not only provide early markers of disease but also appear to act as biological 'clocks' that reflect a person's chronological aging. 'These stem cells give us insights not only into early-stage disease but also into how aging progresses differently in men and women,' explained Dr. Nili Furer of the Weizmann Institute. 'We found that in males, the changes in these cells occur earlier than in females, potentially explaining the higher incidence of blood cancers among men.' The study holds significant promise for the future of cancer diagnostics. By replacing an uncomfortable and invasive procedure with a simple blood test, early detection becomes more accessible and patient-friendly. Furthermore, the researchers believe this breakthrough method could be adapted to detect other age-related blood disorders beyond MDS and AML. A large-scale international clinical trial is already underway to validate the effectiveness of the blood test across multiple medical centers worldwide. If successful, this new method could pave the way for more accurate, less invasive, and earlier diagnoses of life-threatening blood cancers, ultimately improving outcomes and quality of life for countless patients.
Time of India
5 days ago
- Time of India
Acute Myeloid Leukemia: From fatigue to fever, the subtle symptoms to know
It often starts with something as ordinary as tiredness. A lingering fever. Bruises that weren't there yesterday, for many, these signs don't ring alarm bells- until they do. June is observed as AML Awareness Month, A crucial time to talk about acute myeloid leukaemia (AML)- a type of blood cancer that can advance rapidly if ignored. Despite being aggressive, AML doesn't always begin with dramatic symptoms. Some of the earlier signs are subtle, everyday experiences that we often tend to overlook, such as fatigue, fever, minor infections, or even pale skin. But when these persist, it's time to look deeper. What exactly is AML? AML affects the body and bone marrow, leading to the production of abnormal white blood cells that crowd out healthy ones. In simple terms, the body's defence system is compromised from the inside. Dr Sameer Melinkeri, Hemato-oncologist and Director of Bone Marrow Transplant at Sahyadri Hospital, Pune, explains, 'AML symptoms mimic common conditions fever, fatigue, frequent infections, or bruising. Unfortunately, these signs are often dismissed or treated symptomatically, leading to late-stage detection.' Key symptoms include: Persistent fatigue or Weakness Unexplained fever or night sweats Frequent or severe infections Easy bruising or bleeding Pale skin (anaemia) Bone pain Diagnosis and challenges Diagnosis typically begins with a complete blood count, followed by a bone marrow biopsy. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like What Does My Family Name Mean? beenverified Sign Up Undo Additional genetic and molecular testing helps determine the exact subtype and suitable treatment. In India, where fevers are commonly attributed to viral infections like dengue or typhoid, AML is often missed until it progresses, especially in primary healthcare settings. According to estimates from the Indian Council of Medical Research, blood cancers make up around 8-10% of total cancer cases in the country, and AML is a major contributor among adults. Is treatment possible? Yes, but it's not simple. The treatment is costly, says Dr Melinkeri. 'Earlier, AML was treated only with intensive chemotherapy or Bone Marrow Transplant. However, not all individuals, particularly elderly patients, can't manage that intensity of treatment. Only about half the patients can complete the full course due to financial barriers. With the advent targeted therapies such as Ivosidenib, Azacitidine and Venetoclax, individual mutations in AML could be targeted leading do minimal collateral damage to normal blood cells. ' Why does awareness matter more than ever? In a country like ours, a lack of awareness is one of the biggest enemies. People ignore symptoms until it's too late, not because they don't care, but because they don't know what to look for. That is why this June, AML Awareness Month becomes more than just a calendar note. It's a reminder to listen to our body talk to a doctor if something feels off. Even if it is just fatigue. AML might be rare, but when it strikes, it doesn't wait and neither should we.
Time of India
25-06-2025
- Time of India
Hope for AML patients with rare gene mutation
Pune: New and emerging therapies, which cause less collateral damage to normal blood and target specific mutations, are a promising alternative to treat Acute Myeloid Leukemia (AML), several oncologists have said. June is AML awareness month. Specialists have begun using ivosidenib, one such drug, that targets AML with IDH mutation, after Central Drugs Standard Control Organisation approved it in May. You Can Also Check: Pune AQI | Weather in Pune | Bank Holidays in Pune | Public Holidays in Pune India accounts for the highest number of AML cases after the US and China as per statistics from 2021. Dr Sameer Melinkeri, clinical haematologist at Pune's Deenanath Mangeshkar Hospital & Research Centre, said new therapies such as ivosidenib, azacitidine and venetoclax, help precisely target individual mutations in AML. "Ivosidenib is the first targeted therapy developed specifically for AML patients who carry the rare IDH1 gene mutation," said Dr Melinkeri. "It blocks a faulty enzyme—mutant IDH1—that causes the buildup of a harmful substance called 2-hydroxyglutarate in the body. This substance stops blood cells from maturing and spreads cancer cells," the doctor added. He said ivosidenib turns off the cancer-causing switch (mutation) in patients with IDH, a specific gene mutation. By stopping the enzyme, ivosidenib helps blood cells mature normally, reducing cancerous cells and allowing healthy cells to grow. Dr Reshma Puranik, a medical and haemato-oncologist with MOC, Cancer Care and Research Centre said that ivosidenib is a first-in-class, oral, small-molecule inhibitor of the mutant IDH1 enzyme and works well in brain tumors with IDH mutation. In trials, ivosidenib and azacitidine achieved superior outcomes with similar toxicity compared to azacitidine with newly-diagnosed IDH1-mutated AML. "Patients on ivosidenib need to monitor blood counts along with renal and liver function tests, serum electrolytes and QT interval on ECG. Some patients get a minor rash, feel fatigued, have oral mucositis (ulcers) and are at risk of differentiation syndrome," Dr Puranik added. While the new targeted therapies are expensive, more awareness and distributors in the market will bring the cost down, experts say. Dr Shilpa Gupta, consultant haemato-oncologist in a Mumbai-based cancer centre, said, "I have started ivosidenib for a patient and will wait for the results."
